<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121248">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01524289</url>
  </required_header>
  <id_info>
    <org_study_id>0859-020</org_study_id>
    <secondary_id>2011-004525-27</secondary_id>
    <nct_id>NCT01524289</nct_id>
  </id_info>
  <brief_title>Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)</brief_title>
  <acronym>REALIZE</acronym>
  <official_title>A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and tolerability of adding
      anacetrapib to ongoing statin therapy in participants with heterozygous familial
      hypercholesterolemia.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change from Baseline in Low Density Lipoprotein Cholesterol (LDL-C)(beta quantification method)</measure>
    <time_frame>Baseline and Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in High Density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>Baseline and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C)</measure>
    <time_frame>Baseline and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Apolipoprotein B (Apo B)</measure>
    <time_frame>Baseline and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Apolipoprotein A1 (Apo A1)</measure>
    <time_frame>Baseline and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Lipoprotein(a) (Lp[a])</measure>
    <time_frame>Baseline and Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">306</enrollment>
  <condition>Hyperlipoproteinemia Type II</condition>
  <condition>Heterozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Anacetrapib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anacetrapib</intervention_name>
    <description>one 100 mg tablet, orally once daily for 52 weeks</description>
    <arm_group_label>Anacetrapib</arm_group_label>
    <other_name>MK-0859</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Anacetrapib</intervention_name>
    <description>one tablet, orally, once daily for 52 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  If of reproductive potential, must agree to remain abstinent or use (or have their
             partner use) 2 acceptable methods of birth control for the duration of the study

          -  Diagnosed with Heterozygous Familial Hypercholesterolemia (HeFH)

          -  Have been treated with an optimal dose of statin for at least 6 weeks

        Exclusion Criteria:

          -  Received treatment with low-density lipoprotein (LDL) apheresis within 4 weeks of
             screening or expect to undergo treatment with LDL apheresis during the course of the
             study

          -  Homozygous familial hypercholesterolemia

          -  Severe chronic heart failure

          -  Uncontrolled hypertension

          -  Uncontrolled cardiac arrhythmias, myocardial infarction (MI), percutaneous coronary
             intervention (PCI) , coronary artery bypass graft (CABG), unstable angina, or stroke
             within 3 months

          -  Uncontrolled endocrine or metabolic disease known to influence serum lipids or
             lipoproteins

          -  Active or chronic hepatobiliary, hepatic, or gall bladder disease

          -  Pregnant or breast-feeding, or plans to become pregnant during the

        study or within 2 years after stopping study mediation

          -  History of ileal bypass, gastric bypass, or other significant condition associated
             with malabsorption

          -  Human immunodeficiency virus (HIV) positive

          -  History of malignancy â‰¤5 years

          -  Donated blood products or has had phlebotomy of &gt;300 mL within 8

        weeks or intends to donate 250 mL of blood products or receive blood products within the
        projected duration of the study

          -  Currently taking medications that are potent inhibitors or inducers of cytochrome
             P450 3A4 (CYP3A) (including but not limited to cyclosporine, systemic itraconazole or
             ketoconazole, erythromycin, clarithromycin, or telithromycin, nefazodone, protease
             inhibitors, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, St John's
             wort) or has discontinued treatment &lt;3 weeks prior

          -  Consumes more than 2 alcoholic drinks per day

          -  Currently participating or has participated in a study with an investigational
             compound or device within 3 months

          -  Receiving treatment with systemic corticosteroids or taking systemic anabolic agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Kastelein JJ, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh GK, Al-Saady N, Koeijvoets M, Hunter J, Johnson-Levonas AO, Fable J, Sapre A, Mitchel Y. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2015 May 30;385(9983):2153-61. doi: 10.1016/S0140-6736(14)62115-2. Epub 2015 Mar 3.</citation>
    <PMID>25743173</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 7, 2017</lastchanged_date>
  <firstreceived_date>January 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anacetrapib</mesh_term>
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
